New kidney drug QRX-3 shows promise in slowing disease progression
NCT ID NCT06948292
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed Phase 2 trial tested QRX-3, a drug that boosts NAD activity in kidney cells to reduce damage and improve function. 127 adults with chronic kidney disease stages 3-5 took part over 12 months. Researchers measured changes in kidney function and protein levels in urine to see if QRX-3 slows disease worsening compared to no treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QRX-3
What this could lead to
If successful, QRX-3 could offer a new way to slow kidney function decline in chronic kidney disease patients, potentially delaying the need for dialysis or transplant.
What could go wrong
This is a Phase 2 trial with 127 participants, so results are preliminary. The drug may not show significant benefit over placebo, and long-term safety is not yet established.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Neukidney Inc
Pasedena, Texas, 77504, United States